Drug intelligence / Profile preview

autologous iPS-derived cardiomyocytes

Development stage: Unknown
Lead developer: Beijing University of Chinese Medicine
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Autologous iPS-derived cardiomyocytes is an investigational cell therapy developed by the Beijing University of Chinese Medicine for the treatment of chronic heart failure (CHF). The therapy involves the generation of induced pluripotent stem cells (iPSCs) from the patient's own cells, which are then differentiated into functional cardiomyocytes. These cells are administered via intravenous transplantation with the aim of repairing injured myocardial tissue and restoring cardiac function. The treatment is being evaluated in patients with CHF resulting from coronary heart disease, dilated cardiomyopathy, or Keshan disease.

Other names: iPS differentiated cardiomyocytesautologous iPS differentiated cardiomyocytes

Beyond the preview

Go deeper on autologous iPS-derived cardiomyocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous iPS-derived cardiomyocytes.

Explore the full profile